PT1207884E - Uso de antagonistas cgrp e inibidores de libertacao do cgrp para controlo de afrontamentos da menopausa - Google Patents

Uso de antagonistas cgrp e inibidores de libertacao do cgrp para controlo de afrontamentos da menopausa

Info

Publication number
PT1207884E
PT1207884E PT00958385T PT00958385T PT1207884E PT 1207884 E PT1207884 E PT 1207884E PT 00958385 T PT00958385 T PT 00958385T PT 00958385 T PT00958385 T PT 00958385T PT 1207884 E PT1207884 E PT 1207884E
Authority
PT
Portugal
Prior art keywords
cgrp
menopause
tension control
antagonists
liberation
Prior art date
Application number
PT00958385T
Other languages
English (en)
Portuguese (pt)
Inventor
Henri Doods
Klaus Rudolf
Eberlein Wolfgang
Engel Wolfhard
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PT1207884E publication Critical patent/PT1207884E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT00958385T 1999-08-10 2000-08-05 Uso de antagonistas cgrp e inibidores de libertacao do cgrp para controlo de afrontamentos da menopausa PT1207884E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19937304A DE19937304C2 (de) 1999-08-10 1999-08-10 Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen

Publications (1)

Publication Number Publication Date
PT1207884E true PT1207884E (pt) 2004-12-31

Family

ID=7917551

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00958385T PT1207884E (pt) 1999-08-10 2000-08-05 Uso de antagonistas cgrp e inibidores de libertacao do cgrp para controlo de afrontamentos da menopausa

Country Status (32)

Country Link
EP (1) EP1207884B1 (https=)
JP (1) JP2003506403A (https=)
KR (1) KR100713573B1 (https=)
CN (1) CN1166361C (https=)
AR (1) AR025078A1 (https=)
AT (1) ATE281168T1 (https=)
AU (1) AU777709B2 (https=)
BG (1) BG65366B1 (https=)
BR (1) BR0013009A (https=)
CA (1) CA2378428C (https=)
CZ (1) CZ300513B6 (https=)
DE (2) DE19937304C2 (https=)
EA (1) EA007531B1 (https=)
EE (1) EE04928B1 (https=)
ES (1) ES2231243T3 (https=)
HK (1) HK1046854B (https=)
HR (1) HRP20020117A2 (https=)
HU (1) HUP0202397A3 (https=)
IL (1) IL148057A (https=)
MX (1) MXPA02001373A (https=)
MY (1) MY129668A (https=)
NO (1) NO20020605D0 (https=)
NZ (1) NZ517367A (https=)
PL (1) PL198483B1 (https=)
PT (1) PT1207884E (https=)
SK (1) SK285587B6 (https=)
TR (1) TR200200359T2 (https=)
TW (1) TWI285550B (https=)
UA (1) UA73137C2 (https=)
WO (1) WO2001010425A2 (https=)
YU (1) YU8302A (https=)
ZA (1) ZA200200997B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
WO2003050109A1 (en) * 2001-12-12 2003-06-19 Eli Lilly And Company Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
DE10227294A1 (de) * 2002-06-19 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Zubereitungen zur intranasalen Applikation ausgewählter, von Aminosäuren abgeleiteter CGRP-Antagonisten sowie Verfahren zu deren Herstellung
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10300973A1 (de) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2005004869A1 (en) * 2003-07-07 2005-01-20 Boehringer Ingelheim International Gmbh Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients
CN100418948C (zh) * 2003-07-15 2008-09-17 麦克公司 羟基吡啶cgrp受体抗拮抗剂
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7696195B2 (en) 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7491717B2 (en) 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7439237B2 (en) 2005-04-15 2008-10-21 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2132855T3 (es) * 1995-09-07 1999-08-16 Oreal Extracto de iridaceas y composiciones que lo contienen.
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US5710024A (en) * 1996-07-23 1998-01-20 Smithkline Beecham Corporation Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
DE59711622D1 (de) * 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE19911039A1 (de) * 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
CZ2002497A3 (cs) 2002-06-12
JP2003506403A (ja) 2003-02-18
EE04928B1 (et) 2007-12-17
AU6992800A (en) 2001-03-05
HK1046854A1 (en) 2003-01-30
TR200200359T2 (tr) 2002-05-21
WO2001010425A2 (de) 2001-02-15
SK285587B6 (sk) 2007-04-05
ES2231243T3 (es) 2005-05-16
EP1207884B1 (de) 2004-11-03
KR100713573B1 (ko) 2007-05-02
UA73137C2 (en) 2005-06-15
DE50008527D1 (de) 2004-12-09
CZ300513B6 (cs) 2009-06-03
AR025078A1 (es) 2002-11-06
EA200200207A1 (ru) 2002-08-29
HUP0202397A2 (en) 2002-10-28
ZA200200997B (en) 2002-10-30
CN1166361C (zh) 2004-09-15
MXPA02001373A (es) 2002-07-30
IL148057A0 (en) 2002-09-12
HK1046854B (zh) 2005-02-25
TWI285550B (en) 2007-08-21
NO20020605L (no) 2002-02-07
NO20020605D0 (no) 2002-02-07
DE19937304A1 (de) 2001-03-15
MY129668A (en) 2007-04-30
SK1972002A3 (en) 2002-06-04
CA2378428C (en) 2009-10-20
PL364049A1 (en) 2004-12-13
CA2378428A1 (en) 2001-02-15
AU777709B2 (en) 2004-10-28
BR0013009A (pt) 2002-04-30
PL198483B1 (pl) 2008-06-30
EP1207884A2 (de) 2002-05-29
KR20020016947A (ko) 2002-03-06
YU8302A (sh) 2004-12-31
EE200200061A (et) 2003-04-15
BG65366B1 (bg) 2008-04-30
CN1370069A (zh) 2002-09-18
EA007531B1 (ru) 2006-10-27
HRP20020117A2 (en) 2003-10-31
WO2001010425A3 (de) 2002-02-07
DE19937304C2 (de) 2003-08-21
IL148057A (en) 2008-04-13
BG106391A (bg) 2002-09-30
ATE281168T1 (de) 2004-11-15
NZ517367A (en) 2004-09-24
HUP0202397A3 (en) 2006-07-28

Similar Documents

Publication Publication Date Title
PT1207884E (pt) Uso de antagonistas cgrp e inibidores de libertacao do cgrp para controlo de afrontamentos da menopausa
PT1042301E (pt) Novos derivados de acilguanidina como inibidores da absorcao ossea e como antagonistas do receptor da vitronectina
NO20012570D0 (no) Substituerte benzimidazoler og deres anvendelse som PARP- inhibitorer
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
NO20021329D0 (no) Kinaseinhibitorer som terapeutiske midler
DE69934267D1 (de) Wiederlösbarer Spreizanker für chirurgischen Nähfaden
NO20021820L (no) Tyrosinkinaseinhibitorer
EP1109555A4 (en) Novel angiogenesis inhibitors
DE69837781D1 (de) Zielgerät für Implantatvorrichtungen
DE60023709D1 (de) Sicherheitsverankerungsvorrichtung für tragbare gegenstände
DK0736525T3 (da) Benzonitriler som 5-HT-agonister og -antagonister
FR2777444B1 (fr) Ancre de suture vissee
NO20004802L (no) Forankringsanordning
PT1131083E (pt) Utilizacao de compostos de libertacao de hormona de crescimento e seus antagonistas para o tratamento de tumores
BR0004860B1 (pt) dispositivo para o condicionamento e a distribuição de uma composição e uso do dispositivo.
DE50002854D1 (de) Spreizanker
PT1176991E (pt) Dispositivo ceramico para tratamento de feridas
BR9602691A (pt) Bocal com válvula para sonda naso-esofageana
DE50100125D1 (de) Zugangsberechtigungs-buchungsverfahren
DE50015084D1 (de) Demontagevorrichtung für formschlüssig verankernden Dübel
NO20024373L (no) Forankringsanordning
NO20014904L (no) Fremgangsmåte for forspenning av en ankerline
ES1040609Y (es) Dispositivo de anclaje para soportes de redes de proteccion en obras de construccion.
BR9700141A (pt) Dispositivo automático para desinfetar e desodorisar vasos sanitário
IT1306052B1 (it) Dispositivo di ancoraggio